Hanmi Pharm. Co., Ltd. has announced promising research results for its novel obesity treatment, HM17321. This groundbreaking drug not only augments fat loss but also significantly increases lean ...

Novo Nordisk is aware of 100 hospitalizations and 10 deaths resulting from people taking compounded copies of its popular ...

The Danish company’s share price rise of 7 per cent this year lags far behind its rival Eli Lilly’s 36 per cent, as the US company has gradually increased its share of the obesity and diabetes market ...

Novo Nordisk's net profit in the third quarter rose 21% to 27.3 billion kroner, ahead of the 26.79 billion kroner forecast by analysts in a FactSet poll. Sales rose 21% to 71.31 billion kroner, ...

Telehealth platform Hims & Hers will begin offering a generic version of liraglutide, a GLP-1 weight loss drug, to its customers in 2025, Quartz reported Nov. 4.

Medications like Ozempic and Wegovy, which are used to treat type 2 diabetes and boost weight loss, may also help reduce knee ...

AstraZeneca PLC shed GBP15 billion of market capitalization on Tuesday, after investors were underwhelmed by early data from a trial of a weight-loss pill. The company (UK:AZN) said its lead product ...

Only 13 states currently allow Medicaid to cover treatment of obesity using glucagon-like peptide-1 agonist (GLP-1) medications, researchers said.

There's buzz around certain type 2 diabetes drugs, which not only help regulate blood sugar but can also lead to significant ...

These drugs are collectively known as GLP-1 agonists because they mimic the body’s natural hormone GLP-1, which regulates ...

While expected and seen as largely incremental, Jefferies analyst Peter Welford in a Tuesday note to investors said the detailed data for three early-stage assets support moving them into Phase IIb ...

Related Why treatments can fail patients with 'wet' macular degeneration Ozempic, Wegovy might help ease knee arthritis pain ...